Celldex Therapeutics EBITDA 2010-2022 | CLDX

Celldex Therapeutics ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Celldex Therapeutics Annual EBITDA
(Millions of US $)
2021 $-71
2020 $-60
2019 $-51
2018 $-63
2017 $-117
2016 $-128
2015 $-125
2014 $-119
2013 $-80
2012 $-56
2011 $-39
2010 $-1
2009 $-33
Celldex Therapeutics Quarterly EBITDA
(Millions of US $)
2022-03-31 $-22
2021-12-31 $-19
2021-09-30 $-23
2021-06-30 $-13
2021-03-31 $-16
2020-12-31 $-24
2020-09-30 $-14
2020-06-30 $-10
2020-03-31 $-12
2019-12-31 $-12
2019-09-30 $-11
2019-06-30 $-11
2019-03-31 $-17
2018-12-31 $-12
2018-09-30 $-8
2018-06-30 $-16
2018-03-31 $-28
2017-12-31 $-24
2017-09-30 $-31
2017-06-30 $-28
2017-03-31 $-34
2016-12-31 $-33
2016-09-30 $-29
2016-06-30 $-31
2016-03-31 $-34
2015-12-31 $-31
2015-09-30 $-31
2015-06-30 $-32
2015-03-31 $-31
2014-12-31 $-30
2014-09-30 $-29
2014-06-30 $-27
2014-03-31 $-33
2013-12-31 $-21
2013-09-30 $-22
2013-06-30 $-19
2013-03-31 $-18
2012-12-31 $-16
2012-09-30 $-14
2012-06-30 $-12
2012-03-31 $-13
2011-12-31 $-11
2011-09-30 $-10
2011-06-30 $-9
2011-03-31 $-8
2010-12-31 $22
2010-09-30 $-7
2010-06-30 $-8
2010-03-31 $-7
2009-12-31 $-12
2009-09-30 $-6
2009-06-30 $-8
2009-03-31 $-7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.262B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00